ImmunoGen has announced a collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co, a subsidiary of Huadong Medicine, to develop and commercialize the ovarian cancer treatment mirvetuximab soravtansine to patients in China, Hong Kong, Macau, and Taiwan. The partnership will combine ImmunoGen’s expertise in cancer medication development with Huadong Medicine’s familiarity with regulatory agencies and connections to healthcare organizations within the Asian countries. “With extensive regional experience, the right development and regulatory capabilities, and access to a…
You must be logged in to read/download the full post.
The post ImmunoGen Teams Up With Huadong Medicine to Develop Mirvetuximab in China appeared first on BioNewsFeeds.